O
ALXN

OppenheimerFunds’s Alexion Pharmaceuticals ALXN Stock Holding History

OppenheimerFunds’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$365K Sell
2,699
-1,489
-36% -$185K ﹤0.01% 1480
2018
Q4 		$408K Buy
4,188
+1,358
+48% +$161K ﹤0.01% 1451
2018
Q3 		$393K Buy
2,830
+235
+9% +$29.5K ﹤0.01% 1541
2018
Q2 		$322K Buy
2,595
+117
+5% +$13.7K ﹤0.01% 1593
2018
Q1 		$276K Sell
2,478
-102,766
-98% -$12.3M ﹤0.01% 1629
2017
Q4 		$12.6M Buy
105,244
+20,098
+24% +$2.45M 0.02% 707
2017
Q3 		$11.9M Sell
85,146
-32,315
-28% -$4.39M 0.01% 715
2017
Q2 		$14.3M Buy
117,461
+11,088
+10% +$1.29M 0.02% 661
2017
Q1 		$12.9M Buy
106,373
+258
+0.2% +$33.3K 0.02% 709
2016
Q4 		$13M Buy
106,115
+104,017
+4,958% +$12.7M 0.02% 693
2016
Q3 		$257K Sell
2,098
-87
-4% -$11.2K ﹤0.01% 1557
2016
Q2 		$255K Buy
2,185
+542
+33% +$76.9K ﹤0.01% 1529
2016
Q1 		$224K Buy
1,643
+404
+33% +$59.3K ﹤0.01% 1561
2015
Q4 		$237K Buy
+1,239
New +$216K ﹤0.01% 1608
2013
Q4 		– Sell
-67,620
Closed -$7.86M – 969
2013
Q3 		$7.86M Sell
67,620
-12,680
-16% -$1.39M 0.01% 755
2013
Q2 		$7.41M Buy
+80,300
New +$7.74M 0.01% 727

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OppenheimerFunds's ALXN Position: Q1 2019 in Review

OppenheimerFunds reduced its Alexion Pharmaceuticals (ALXN) stake by 36% in Q1 2019, selling an estimated $185K and leaving 2,699 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

OppenheimerFunds first reported a position in ALXN in Q2 2013 and has held it in 16 quarters since. The position peaked at $14.3M in Q2 2017. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • OppenheimerFunds held 2,699 shares of Alexion Pharmaceuticals worth $365K as of Q1 2019.
  • OppenheimerFunds sold 1,489 Alexion Pharmaceuticals shares in Q1 2019, an estimated $185K.
  • Alexion Pharmaceuticals made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1480 holding.
  • OppenheimerFunds first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • OppenheimerFunds's Alexion Pharmaceuticals position peaked at $14.3M in Q2 2017.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.